$AZTA

Azenta, Inc.

Azenta provides biological and chemical compound sample exploration and management solutions for pharmaceutical, biotechnology, life sciences research, academic and government customers. Headquartered in Burlington, Massachusetts, it operates in North America, Asia and Europe and has sales in approximately 95 countries. Its continuing operations comprise Sample Management Solutions and Multiomics. Sample Management Solutions offers sample repository services, including storage, cold-chain logistics, transport and informatics, along with automated stores, cryogenic systems, sample tubes, consumables, instruments and controlled-rate thawing devices. Multiomics provides gene sequencing, gene synthesis, bioinformatics and related sample analysis services. Azenta makes money by selling products and services, primarily through its direct sales force, with distributors also supporting sales of consumables and instruments.

0
0
1

No SEC Form 4 filings for $AZTA in the last 30 days.

See all $AZTA insider activity →
Med

Azenta FY 2026: Revenue $621.7M, EPS ($3.7) — 10-K Summary

Azenta reported FY 2026 revenue of $621.7M, up 4.7% YoY, but net loss widened to $166.99M due to a $149.1M goodwill impairment charge. Both segments saw revenue growth, while gross margin declined to 44.2%. The company expects $11M in annual cost savings from a restructuring plan.

AZTA sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning AZTA (Azenta, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.

Recent AZTA coverage spans earnings, financial news and market movers.

What's driving AZTA

  • Impairment-driven earnings deterioration likely pressures near-term sentiment, while modest revenue growth and restructuring cost savings may partially offset.

    tradingview.com · Nov 19, 2026

  • Strong results and cash‑flow outlook drove a notable rally.

    stockstory.org · Nov 13, 2026

  • Azenta may see additional weakness amid heightened risk aversion in tech‑heavy portfolios.

    stockstory.org · Nov 12, 2026

  • Jefferies reaffirmed its Buy rating on Azenta and increased its price target to $52 from $44, representing an 18.2% increase. The new target suggests a 28.5% upside from the Nov 10 closing price of $40.48, according to the firm.

    tradingview.com · Nov 11, 2026

  • Forward revenue and margin expansion guidance supports a constructive re-rating, even with a decline in FY26 adjusted EBITDA.

    rttnews.com · Nov 11, 2026

AlphAI scores every news story that mentions AZTA with an AI model for sentiment and relevance, and aggregates insider trades from Azenta, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $AZTA

Score

Insider Buying Signals: 3 Healthcare Stocks to Watch

Prothena (PRTA), Rapport (RAPP), and Azenta (AZTA) are on a watchlist due to insider buying and share repurchases. PRTA's 10% owner bought 27,000 shares at $9.47, with $272.2M cash and no debt. RAPP insiders bought $1.66M in shares, with $815.4M in cash post-financing. AZTA repurchased 2.3M shares, with $529M in cash. All await catalysts: PRTA's Alzheimer's trial data, RAPP's epilepsy study, and AZTA's fiscal 2027 outlook.

Azenta (NASDAQ:AZTA) reports upbeat Q3 CY2026, stock jumps 10.3%

Azenta (AZTA) reported Q3 CY2026 revenue of $167.1M, up 5.1% YoY and beating estimates by 4.3%. Adjusted EPS of $0.28 exceeded forecasts. Stock rose 10.3% post-results. Management highlighted improved momentum and strategic initiatives. Long-term revenue growth has been modest at 3.9% CAGR over five years, with declining operating margins and EPS.

$AZTAMedM&A· acquirer · completed

Azenta, Inc. (AZTA): Entry into a Material Definitive Agreement

Azenta, Inc. (AZTA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Azenta Announces Strategic Investments to Advance the Next Generation of GENEWIZ Gene Synthesis Capabilities Exclusive licensing agreement with Elegen and acquisition of SynPlexity strengthen gene synthesis capabilities, expand high-throughput discovery workflows, and position GE

Related tickers